Treatment of extensive small cell lung cancer

Hematology/Oncology Clinics of North America

Volumn 18, Issue 2, 2004, Pages 373-385

  Davies, Angela M ^a   Lara, Primo N ^a   Lau, Derick H ^a   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE DERIVATIVE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; MESNA; PACLITAXEL; PLATINUM DERIVATIVE; ROXITHROMYCIN; TOPOTECAN; VINCRISTINE; VINDESINE;

ANEMIA; ANOREXIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMORBIDITY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 1942503924     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2003.12.012     Document Type: Review

References (41)

1. Page N., Read W., Tierney R., Arquette M., Piccirillo J., Govindan R. The epidemiology of small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 21:2002;305a.
2. Clark R., Ihde D.C. Small-cell lung cancer: treatment progress and prospects. Oncology (Huntingt). 12(5):1998;647-658.
3. Micke P., Faldum A., Metz T., Beeh K.M., Bittinger F., Hengstler J.G.et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer-what limits limited disease? Lung Cancer. 37(3):2002;271-276.
4. Turrisi A.T. III, Kim K., Blum R., Sause W.T., Livingston R.B., Komaki R.et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 340(4):1999;265-271.
5. Albain K.S., Crowley J.J., LeBlanc M., Livingston R.B. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group database. J Clin Oncol. 8(9):1990;1563-1574.
6. Schiller J.H., Adak S., Cella D., DeVore R.F. III, Johnson D.H. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 19(8):2001;2114-2122.
7. Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P.et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 15(5):1997;2090-2096.
8. Hainsworth J.D., Burris H.A. III, Erland J.B., Baker M., Scullin D.C. Jr., Shaffer D.W.et al. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest. 21(2):2003;193-199.
9. Cerny T., Blair V., Anderson H., Bramwell V., Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 39(2):1987;146-149.
10. Paesmans M., Sculier J.P., Lecomte J., Thiriaux J., Libert P., Sergysels R.et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 89(3):2000;523-533.
11. Albain K.S., Crowley J.J., LeBlanc M., Livingston R.B. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 9(9):1991;1618-1626.
12. Pujol J.L., Carestia L., Daures J.P. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer. 83(1):2000;8-15.
13. Mascaux C., Paesmans M., Berghmans T., Branle F., Lafitte J.J., Lemaitre F.et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer. 30(1):2000;23-36.
14. Chute J.P., Chen T., Feigal E., Simon R., Johnson B.E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol. 17(6):1999;1794-1801.
15. Skarlos D.V., Samantas E., Kosmidis P., Fountzilas G., Angelidou M., Palamidas P.et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Cooperative Oncology Group study. Ann Oncol. 5(7):1994;601-607.
16. Postmus P.E., Smit E.F., Kirkpatrick A., Splinter T.A. Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer. 29A(2):1993;204-207.
17. Roth B.J., Johnson D.H., Einhorn L.H., Schacter L.P., Cherng N.C., Cohen H.J.et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 10(2):1992;282-291.
18. Evans W.K., Feld R., Murray N., Willan A., Coy P., Osoba D.et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann Intern Med. 107(4):1987;451-458.
19. Fukuoka M., Furuse K., Saijo N., Nishiwaki Y., Ikegami H., Tamura T.et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 83(12):1991;855-861.
20. Murray N., Livingston R.B., Shepherd F.A., James K., Zee B., Langleben A.et al. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol. 17(8):1999;2300-2308.
21. Klasa R.J., Murray N., Coldman A.J. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol. 9(3):1991;499-508.
22. Furuse K., Fukuoka M., Nishiwaki Y., Kurita Y., Watanabe K., Noda K.et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol. 16(6):1998;2126-2132.
23. Souhami R.L., Rudd R., Ruiz de Elvira M.C., James L., Gower N., Harper P.G.et al. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol. 12(9):1994;1806-1813.
24. Sculier J.P., Paesmans M., Bureau G., Dabouis G., Libert P., Vandermoten G.et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol. 11(10):1993;1858-1865.
25. Murray N., Shah A., Osoba D., Page R., Karsai H., Grafton C.et al. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol. 9(9):1991;1632-1638.
26. Johnson D.H., Einhorn L.H., Birch R., Vollmer R., Perez C., Krauss S.et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 5(11):1987;1731-1738.
27. Ihde D.C., Mulshine J.L., Kramer B.S., Steinberg S.M., Linnoila R.I., Gazdar A.F.et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 12(10):1994;2022-2034.
28. Ardizzoni A., Tjan-Heijnen V.C., Postmus P.E., Buchholz E., Biesma B., Karnicka-Mlodkowska H.et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group phase III trial-08923. J Clin Oncol. 20(19):2002;3947-3955.
29. Tjan-Heijnen V.C., Postmus P.E., Ardizzoni A., Manegold C.H., Burghouts J., van Meerbeeck J.et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol. 12(10):2001;1359-1368.
30. Sculier J.P., Paesmans M., Lecomte J., Van Cutsem O., Lafitte J.J., Berghmans T.et al. A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Br J Cancer. 85(10):2001;1444-1451.
31. Lorigan P., Woll P., O'Brien M., Hodgetts J., Lomax L., Ashcroft L.et al. Randomised phase 3 trial of dose dense ICE chemotherapy versus standard ICE in good prognosis small cell lung cancer (SCLC) [abstract 2490]. Proc Am Soc Clin Oncol. 22:2003.
32. Thatcher N., Quinn H., Girling D.J.et al. Ifosfamide, carboplatin and etoposide with mid-cycle vincristine (ICE-V) versus standard chemotherapy (C) in patients with small cell lung cancer (SCLC) and good performance status (PS): results of an MRC randomized trial (LU21) [abstract 2489]. Proc Am Soc Clin Oncol. 22:2003.
33. Loehrer P.J. Sr., Ansari R., Gonin R., Monaco F., Fisher W., Sandler A.et al. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol. 13(10):1995;2594-2599.
34. Smit E.F., Fokkema E., Biesma B., Groen H.J., Snoek W., Postmus P.E. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 77(2):1998;347-351.
35. Niell H.B., Herndon J.E., Miller A.A., Watson D.M., Sandler A., Kelly K.et al. Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC) [abstract 1169]. Proc Am Soc Clin Oncol. 21:2002.
36. Hanna N.H., Sandier A.B., Loehrer P.J. Sr., Ansari R., Jung S.H., Lane K.et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol. 13(1):2002;95-102.
37. Giaccone G., Dalesio O., McVie G.J., Kirkpatrick A., Postmus P.E., Burghouts J.T.et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 11(7):1993;1230-1240.
38. Sculier J.P., Paesmans M., Bureau G., Giner V., Lecomte J., Michel J.et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol. 14(8):1996;2337-2344.
39. Sculier J.P., Berghmans T., Castaigne C., Luce S., Sotiriou C., Vermylen P.et al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer. 19(2):1998;141-151.
40. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A.et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 346(2):2002;85-91.
41. James L., Rudd R., Gower N., Gregory W., Lee S., Eisen T.et al. A phase III randomised comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC) [abstract 1170]. Proc Am Soc Clin Oncol. 21:2002.